Colon Cancer Home > Vectibix and Breastfeeding
It is unknown if Vectibix (panitumumab) passes through human breast milk. This medicine is a manufactured version of a naturally occurring antibody, which is known to pass through breast milk. Therefore, it is possible that Vectibix would pass through breast milk. Due to the potentially serious side effects associated with Vectibix, breastfeeding women should talk to their healthcare provider before receiving this drug.
Can Breastfeeding Women Receive Vectibix?Vectibix® (panitumumab) is a prescription medication approved for use as a single agent in people who have certain types of colorectal cancer. The manufacturer of the medicine recommends that women should not breastfeed while receiving Vectibix, and for at least two months after the last dose is given.
More Information on Vectibix and BreastfeedingVectibix has not been studied in breastfeeding women. Therefore, it is unknown whether the drug passes through breast milk or if it would harm a nursing child.
Vectibix is a type of human antibody (a protein made by the immune system) known as immunoglobulin G (IgG). IgG is known to pass into human breast milk in a small amount. Therefore, it is possible that Vectibix would also pass into breast milk.
However, very little antibody normally reaches the infant's bloodstream from the ingested breast milk. This is because the antibody is usually not well absorbed through the gastrointestinal (GI) tract. It is unknown whether the same would be true for Vectibix.
It is also important to keep in mind that Vectibix can cause potentially serious side effects, including life-threatening skin reactions. Until more information is known about using this drug while nursing, the risk for these side effects in a nursing infant cannot be ruled out.